Baker Botts Partner Rob Maier breaks down the Supreme Court's unanimous ruling that induced patent infringement requires clear, affirmative encouragement rather than vague statements or omissions, with implications reaching well beyond generic drug skinny labels into any industry with dual-use products.

For a complete copy of this article from New York Law Journal, please click the title link below:

The Supreme Court’s Decision in 'Hikma v. Amarin' and What it May Mean for Patent Enforcement Strategy